Botox 100 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FKKE8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,163
Award facts
- Contract value 100% obligated
- $14,162.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $14,162.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Botox 100 Unit Vials. The award, issued on December 5, 2025, represents a firm fixed-price delivery order with an ultimate completion date of December 29, 2025. This delivery order was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., which has been registered in the System for Award Management since July 2001, serves as a critical supplier within the federal pharmaceutical supply chain, specializing in distributing pharmaceutical products and medical consumables to Department of Defense facilities.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, and positions the company as one of multiple regional prime vendor contractors supporting the broader $30.3 billion PPV-G GEN V acquisition strategy. This contract structure enables DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products, including branded and generic medications, biologics, and medical consumables, to support recurring medical supply needs of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FKKE8?
SPE2DR26FKKE8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FKKE8 worth?
The government has obligated $14,163 on SPE2DR26FKKE8.
Is contract SPE2DR26FKKE8 an order under another contract?
Yes. SPE2DR26FKKE8 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKE8 competed?
The extent of competition for SPE2DR26FKKE8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award